adMare
News

News - Thumbnail

December 02 2024

KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications

Read
News - Thumbnail

November 28 2024

adMare BioInnovations Spins Out Analytical Services to Paraza Pharma, Catalyzing Growth and Innovation

Read
News - Thumbnail

November 21 2024

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Read
News - Thumbnail

November 15 2024

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025ucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing

Read
News - Thumbnail

November 12 2024

Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing

Read
News - Thumbnail

October 25 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Read
News - Thumbnail

October 24 2024

Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic

Read
News - Thumbnail

October 23 2024

Epitopea Closes USD $31 million Pre-Series A Financing

Read
News - Thumbnail

October 22 2024

adMare BioInnovations Celebrates Successes of adMare Tx Accelerator Companies, Concludes Ontario Partnership with MaRS

Read
News - Thumbnail

October 21 2024

Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

Read
News - Thumbnail

October 15 2024

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Read
News - Thumbnail

October 02 2024

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment 

Read